{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:46:45Z","timestamp":1790999205600,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["52817"],"award-info":[{"award-number":["52817"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["IR.TUMS.DDRI.REC.1400.018"],"award-info":[{"award-number":["IR.TUMS.DDRI.REC.1400.018"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.schres.2023.02.020","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T22:15:52Z","timestamp":1676844952000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"254","author":[{"given":"Monire","family":"Karbalaee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Jameie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Amanollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"TaghaviZanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadamin","family":"Parsaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh A.","family":"Basti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza Khodaei","family":"Ardakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0005","first-page":"295","article-title":"The 5-HT hypothesis of schizophrenia","volume":"4","author":"Akhondzadeh","year":"2001","journal-title":"IDrugs"},{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.9758\/cpn.2013.11.3.144","article-title":"Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures","volume":"11","author":"Al-Amin","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"6","key":"10.1016\/j.schres.2023.02.020_bb0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bdi.12324","article-title":"Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Arabzadeh","year":"2015","journal-title":"Bipolar Disord."},{"issue":"20","key":"10.1016\/j.schres.2023.02.020_bb0020","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.schres.2023.02.020_bb0025","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.psyneuen.2012.04.001","article-title":"Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome","volume":"37","author":"Beumer","year":"2012","journal-title":"Psychoneuroendocrinology"},{"issue":"14","key":"10.1016\/j.schres.2023.02.020_bb0030","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"\u00c7akici","year":"2019","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0035","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3892\/etm.2021.9707","article-title":"Current perspectives in treating negative symptoms of schizophrenia: a narrative review (Review)","volume":"21","author":"C\u0103p\u0103\u021b\u00een\u0103","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"8","key":"10.1016\/j.schres.2023.02.020_bb0040","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.02.020_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the extrapyramidal symptom rating scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2023.02.020_bb0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"3\u20134","key":"10.1016\/j.schres.2023.02.020_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.prostaglandins.2009.04.002","article-title":"Sphingosine-1-phosphate and oligodendrocytes: from cell development to the treatment of multiple sclerosis","volume":"91","author":"Coelho","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.schres.2023.02.020_bb0060","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3389\/fphar.2018.01172","article-title":"Confused connections? Targeting white matter to address treatment resistant schizophrenia","volume":"9","author":"Crocker","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.schres.2023.02.020_bb0065","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/schbul\/sbaa052","article-title":"Evidence for altered metabolism of Sphingosine-1-phosphate in the corpus callosum of patients with schizophrenia","volume":"46","author":"Esaki","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.02.020_bb0070","series-title":"Structured Clinical Interview for DSM-5\u2014Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)","first-page":"1","author":"First","year":"2015"},{"issue":"4","key":"10.1016\/j.schres.2023.02.020_bb0075","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11682-020-00375-7","article-title":"Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia","volume":"15","author":"Francis","year":"2021","journal-title":"Brain Imaging Behav."},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.02.020_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2009.09.022","article-title":"Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study","volume":"115","author":"Galderisi","year":"2009","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2023.02.020_bb0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/schbul\/sbt001","article-title":"Pro-\/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia","volume":"40","author":"Garc\u00eda-Bueno","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2023.02.020_bb0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-0042-116159","article-title":"Crocus sativus L. Versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial","volume":"50","author":"Ghajar","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.schres.2023.02.020_bb0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/schbul\/sbs118","article-title":"Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects","volume":"39","author":"Haijma","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2023.02.020_bb0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2023.02.020_bb0105","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0006-3223(03)00237-3","article-title":"Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia","volume":"53","author":"Hof","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.02.020_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2023.02.020_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.schres.2023.02.020_bb0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.schres.2023.02.020_bb0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2023.02.020_bb0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/schbul\/sbu070","article-title":"Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage","volume":"40","author":"Kochunov","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171552","article-title":"Fingolimod effects in neuroinflammation: regulation of astroglial glutamate transporters?","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"issue":"2 Suppl","key":"10.1016\/j.schres.2023.02.020_bb0140","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"13","key":"10.1016\/j.schres.2023.02.020_bb0145","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.7.13.1739","article-title":"A review of atypical antipsychotic drugs versus conventional medication in schizophrenia","volume":"7","author":"Luft","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.schres.2023.02.020_bb0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.02.020_bb0155","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.2353\/ajpath.2010.091234","article-title":"Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices","volume":"176","author":"Miron","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","article-title":"Cytokines and schizophrenia: microglia hypothesis of schizophrenia","volume":"63","author":"Monji","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/YIC.0000000000000399","article-title":"Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"37","author":"Motamed","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.02.020_bb0170","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"M\u00fcller","year":"2015","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2023.02.020_bb0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2710.1999.00238.x","article-title":"Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia","volume":"24","author":"Noorbala","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"issue":"9","key":"10.1016\/j.schres.2023.02.020_bb0180","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P t"},{"issue":"6","key":"10.1016\/j.schres.2023.02.020_bb0185","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","article-title":"Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models","volume":"24","author":"Pillinger","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2023.02.020_bb0190","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/mds.25445","article-title":"Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with lewy bodies","volume":"28","author":"Postuma","year":"2013","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.schres.2023.02.020_bb0195","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.020_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114737","article-title":"Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: a randomized, double-blinded, placebo-controlled trial","volume":"316","author":"Salehi","year":"2022","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.schres.2023.02.020_bb0205","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ijnp\/pyaa006","article-title":"Resveratrol adjunct therapy for negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial","volume":"23","author":"Samaei","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2023.02.020_bb0210","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","article-title":"Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"25","author":"Scott","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2023.02.020_bb0215","series-title":"Readings in General Psychology","article-title":"The intelligence quotient","author":"Stern","year":"1949"},{"issue":"1","key":"10.1016\/j.schres.2023.02.020_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pneurobio.2010.09.004","article-title":"Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia","volume":"93","author":"Takahashi","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.schres.2023.02.020_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-017-0817-6","article-title":"Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation","volume":"14","author":"Thomas","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"9386","key":"10.1016\/j.schres.2023.02.020_bb0230","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(03)14289-4","article-title":"Oligodendrocyte dysfunction in schizophrenia and bipolar disorder","volume":"362","author":"Tkachev","year":"2003","journal-title":"Lancet"},{"issue":"9690","key":"10.1016\/j.schres.2023.02.020_bb0235","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2023.02.020_bb0240","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jmri.27028","article-title":"Functional alterations of white matter in chronic never-treated and treated schizophrenia patients","volume":"52","author":"Yang","year":"2020","journal-title":"J. Magn. Reson. Imaging"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:37:28Z","timestamp":1777581448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":48,"alternative-id":["S0920996423000622"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.02.020","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}